Nuveen
UTMD icon

Nuveen’s Utah Medical Products UTMD Stock Holding History

Nuveen’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Hold
4,601
– – ﹤0.01% 3485
2026
Q1 		$285K Sell
4,601
-1,068
-19% -$67.3K ﹤0.01% 3021
2025
Q4 		$317K Hold
5,669
– – ﹤0.01% 3032
2025
Q3 		$357K Hold
5,669
– – ﹤0.01% 3006
2025
Q2 		$323K Sell
5,669
-2,349
-29% -$128K ﹤0.01% 3020
2025
Q1 		$449K Sell
8,018
-871
-10% -$52.2K ﹤0.01% 2937
2024
Q4 		$546K Sell
8,889
-3,780
-30% -$244K ﹤0.01% 2955
2024
Q3 		$848K Hold
12,669
– – ﹤0.01% 2829
2024
Q2 		$846K Buy
12,669
+1,340
+12% +$91.2K ﹤0.01% 2797
2024
Q1 		$806K Hold
11,329
– – ﹤0.01% 2784
2023
Q4 		$954K Buy
11,329
+2,490
+28% +$207K ﹤0.01% 2751
2023
Q3 		$760K Hold
8,839
– – ﹤0.01% 2687
2023
Q2 		$824K Hold
8,839
– – ﹤0.01% 2737
2023
Q1 		$838K Sell
8,839
-125
-1% -$11.5K ﹤0.01% 2668
2022
Q4 		$901K Sell
8,964
-810
-8% -$73.9K ﹤0.01% 2722
2022
Q3 		$834K Buy
9,774
+98
+1% +$8.65K ﹤0.01% 2825
2022
Q2 		$831K Sell
9,676
-1,982
-17% -$169K ﹤0.01% 2872
2022
Q1 		$1.03M Buy
11,658
+125
+1% +$11.5K ﹤0.01% 2812
2021
Q4 		$1.25M Sell
11,533
-2,496
-18% -$255K ﹤0.01% 2775
2021
Q3 		$1.25M Sell
14,029
-1,620
-10% -$143K ﹤0.01% 2902
2021
Q2 		$1.33M Buy
15,649
+1,697
+12% +$147K ﹤0.01% 2893
2021
Q1 		$1.21M Sell
13,952
-806
-5% -$70.9K ﹤0.01% 2830
2020
Q4 		$1.24M Buy
14,758
+977
+7% +$83.3K ﹤0.01% 2727
2020
Q3 		$1.1M Buy
13,781
+574
+4% +$47.6K ﹤0.01% 2643
2020
Q2 		$1.17M Sell
13,207
-283
-2% -$25.4K ﹤0.01% 2562
2020
Q1 		$1.27M Buy
13,490
+6,752
+100% +$627K ﹤0.01% 2407
2019
Q4 		$727K Sell
6,738
-6,180
-48% -$626K ﹤0.01% 2800
2019
Q3 		$1.24M Sell
12,918
-756
-6% -$70.3K ﹤0.01% 2606
2019
Q2 		$1.31M Buy
+13,674
New +$1.15M ﹤0.01% 2627

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's UTMD Position: Q2 2026 in Review

Nuveen held its Utah Medical Products (UTMD) position steady in Q2 2026 at 4,601 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Nuveen first reported a position in UTMD in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.33M in Q2 2021. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Nuveen held 4,601 shares of Utah Medical Products worth $317K as of Q2 2026.
  • Nuveen left its Utah Medical Products share count unchanged in Q2 2026.
  • Utah Medical Products made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3485 holding.
  • Nuveen first reported a position in Utah Medical Products in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Utah Medical Products position peaked at $1.33M in Q2 2021.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.